IL41902A - Immunogenic substance,its production,vaccine preparations containing it and their preparation - Google Patents
Immunogenic substance,its production,vaccine preparations containing it and their preparationInfo
- Publication number
- IL41902A IL41902A IL41902A IL4190273A IL41902A IL 41902 A IL41902 A IL 41902A IL 41902 A IL41902 A IL 41902A IL 4190273 A IL4190273 A IL 4190273A IL 41902 A IL41902 A IL 41902A
- Authority
- IL
- Israel
- Prior art keywords
- vaccine
- substance
- immunogenic substance
- multocida
- immunogenic
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims 30
- 229960005486 vaccine Drugs 0.000 title claims 30
- 230000002163 immunogen Effects 0.000 title claims 22
- 238000002360 preparation method Methods 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims 13
- 241000606856 Pasteurella multocida Species 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 6
- 241001293418 Mannheimia haemolytica Species 0.000 claims 5
- 238000002649 immunization Methods 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 231100000419 toxicity Toxicity 0.000 claims 4
- 230000001988 toxicity Effects 0.000 claims 4
- 206010034107 Pasteurella infections Diseases 0.000 claims 3
- 244000309725 Pasteurella multocida type A Species 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 201000005115 pasteurellosis Diseases 0.000 claims 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 208000008939 Pneumonic Pasteurellosis Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 241000206044 Clostridium chauvoei Species 0.000 claims 1
- 241000193466 Clostridium septicum Species 0.000 claims 1
- 208000032969 Hemorrhagic Septicemia Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000006666 Shwartzman Phenomenon Diseases 0.000 claims 1
- 231100000702 Shwartzman phenomenon Toxicity 0.000 claims 1
- 159000000013 aluminium salts Chemical group 0.000 claims 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000003837 chick embryo Anatomy 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 231100000636 lethal dose Toxicity 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 229940051027 pasteurella multocida Drugs 0.000 claims 1
- 230000001698 pyrogenic effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (9)
1. A386 PI What we claim is:- 1. An immunogenic substance suitable for use in conferring immunity in a mammal or bird against pasturellosis arising from infection with Pasteurella multocida or Pasteurella haemolytica which substance is obtainable from an encapsulated variant of a serotype selected from P.multocida and P .haemolytica serotypes , said serotype corresponding to the serotype against which immunity is to be conferred by said substance; is nontoxic in mammals and birds at the immunising dose of said substance; is antigenically stable after 10 minutes in water at 100°C; is non-dialysable; is water soluble; and is substantially absent from non-capsulated variants of P .multocida and .haemolytica.
2. An immunogenic substance as claimed in claim 1 wherein an immunising dose of the substance has a toxicity less than one tenth of the toxicity associated with an immunising dose of a culture of encapsulated P.multocida or P .haemolytica from which endotoxin has not been removed.
3. An immunogenic substance as claimed in claim 1 wherein an immunising dose of the substance has a toxicity less than one hundredth of the toxicity associated with an immunising dose of a culture of encapsulated P .multocida or P. haemolytica from which endotoxin has not been removed.
4. An immunogenic substance as claimed in either of claims 1 and 2 wherein the substance has an LD50 of more than 5 yg. in chick embryos by the method of Milner and Finkelstein; a reactive dose of more than 100 yg. in the localised Schwartzman reaction; a pyrogenic index in rabbits of less than 20 by the method of Milner and Finkelstein when using a dose of 5 yg; or a lethal dose for rabbits when administered intravenously of more than A386 PI 1 mg.
5. An immunogenic substance as claimed in any of claims 1 to 4 wherein the substance has a molecular weight of from 4 7 10 to 10 .
6. An immunogenic substance as claimed in any of claims 1 to 5 wherein the encapsulated variant is of P.multocida Type A (Carter) or Type D (Carter) .
7. An immunogenic substance as claimed in any of claims 1 to 5 wherein the encapsulated variant is a serotype selected from P.multocida Types B and E (Carter).
8. An immunogenic substance as claimed in any of claims 1 to 5 wherein the encapsulated variant is a P.haemolytlea serotype.
9. An immunogenic substance as claimed in any of claims 1 to 8 wherein the immunogenic substance has a solubility in distilled water of at least 20 mg/ml. A 386 P2 10. A sterile vaccine suitable for immunisation of a mammal or bird against pasteurellosis arising from infection with P. multocida or P. haemolytica comprising an immunogenic substance according to any of Claims 1 to 9 in association with a physiologically acceptable carrier, said vaccine being sterile and isotonic with blood of the mammal or bird to be immunised. 11 . A vaccine according to Claim 10 characterised in that the vaccine is in a freeze-dried form for reconstitution with pyrogen-free water. 12. A vaccine according to Claim 10 characterised in that the carrier comprises pyrogen-free water. 13· A vaccine according o any of Claims 10 to 12 characterised in that the vaccine includes an adjuvant. 1 . A vaccine according to Claim 13 characterised in that the adjuvant is an aluminium salt or base. 15. A vaccine according to any of Claims 10 and 12 to 14 characterised in that the vaccine comprises a water-in-oil emulsion wherein the immunogenic substance is present in the aqueous phase. 16. A vaccine according to Claim 15 characterised in that the and/ vaccine includes a lipophilic/or hydrophilic emulsifier. 17. A vaccine according to any of Claims 10 to 16 characterised in that it is presented in unit dosage form. 18. A vaccine according to Claim 17 characterised in that . '■ — —: — · the- unit dosage contains from A 386 P2 1 to 100 mg. of dialysed and i'reeze-dried immunogenic substance. 19. A vaccine according to Claim 18 characterised in that dialysed and freeze-dried the unit dosage contains from 2 to 20 mg. of / immunogenic substance. 20. A vaccine according to any of Claims 10 to 19 characterised in that the vaccine contains an additional immunising substance of bacterial or viral origin. 21. A vaccine according to Claim 20 characterised in that the other active ingredient is of a Clostridium chauvoei vaccine. 22. A vaccine according to Claim 20 characterised in that the encapsulated variant is of P. multocida Type B or E (Carter) cells and the other active ingredient is of an Anthrax spores vaccine . . 23. A vaccine according to Claim 20 characterised in that the encapsulated variant is of P. multocida Type A or D (Carter) cells and the other active ingredient is of a Clostridium septicum vaccine. 24-. A method of preparing a vaccine according to any of Claims 10 to 23, suitable for the immunisation of a mammal or bird against pasteurellosis characterised in that one brings an immunogenic substance according to any of Claims 1 to 9 into association with a physiologically acceptable carrier and renders the vaccine sterile and isotonic with the blood of the mammal or bird to be immunised. A 386 P3 25· An immunogenic substance substantially as described herein with reference to Examples 1, 2, 3 and 6. 26. A method of preparing an immunogenic substance substantial! as described herein with reference to Examples 1, 2, 3 and 6. 2 · A vaccine substantially as described herein with reference to Example 4. 28. A method of preparing a vaccine substantially as described herein with reference to Example 4-, 41902/2 - 45 - 29. A method of inraamisation of non-humans and birds against pasteurellosis comprising administration of an effective dosage of a sterile vaccine according to any Claims 10 to 24. 30. A method of immunisation of non-human mammals against shipping fever, according to Claim 29, characterized in that th encapsulated variant is of P. multocida Type A or D (Carter) serotype. 31. A method of immunisation of non-human mammals against Haemorrhagic septicaemia according to Claiji 29 characterized in that the encapsulated variant is of a P. Multocida Type B or E (Carter) serotype. 32. , A method of immunisation of non-human mammals against pneumonic pasteurellosis, according to Claim 29 characterized in that the encapsulated variant is of a P. Haamolytica serotype. 33. A method according to any of Claim 29 to 32 characterized in that the vaccine is administered intramuscularly or subcutaneously. 34. A method according to any of Claims 29 to 33 characterized in that the dosage is from 1 to loo rag. of dialysed and freeze-dried immunogenic substance. 35. A method according to Claim 34 characterized in that the dosage is from 2 to 20 mg. of dialysed and freeze-dried immunogenic substance. 36. A method according to any of Claims 29 to 33 characterized in that the amount of immunogenic substance per dose corresponds 6 to the amount of immunogenic substance obtainable from, from 10 to 1011 cells of said encapsulated variant. Ppr tJhe Applicants
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1491072 | 1972-03-29 | ||
| GB593573*[A GB1441098A (en) | 1972-03-29 | 1973-02-07 | Biological preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL41902A0 IL41902A0 (en) | 1973-05-31 |
| IL41902A true IL41902A (en) | 1976-03-31 |
Family
ID=26240265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL41902A IL41902A (en) | 1972-03-29 | 1973-03-28 | Immunogenic substance,its production,vaccine preparations containing it and their preparation |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS496118A (en) |
| DE (1) | DE2315563A1 (en) |
| ES (1) | ES413100A1 (en) |
| FR (1) | FR2182909B1 (en) |
| GB (1) | GB1441098A (en) |
| HU (1) | HU171383B (en) |
| IL (1) | IL41902A (en) |
| IT (1) | IT1035061B (en) |
| NL (1) | NL7304320A (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2964721D1 (en) * | 1978-08-24 | 1983-03-17 | Nat Res Dev | Pasteurellosis vaccines |
| US4328210A (en) | 1980-03-31 | 1982-05-04 | Norden Laboratories, Inc. | Modified Pasteurella bacteria and vaccines prepared therefrom |
| US4335106A (en) | 1980-03-31 | 1982-06-15 | Norden Laboratories Inc. | Processes for the growth of a modified Pasteurella multocida bacteria and preparation of a vaccine therefrom |
| US4388299A (en) | 1980-03-31 | 1983-06-14 | Norden Laboratories, Inc. | Modified pasteurella bacteria and vaccines prepared therefrom |
| US4293545A (en) | 1980-03-31 | 1981-10-06 | Norden Laboratories, Inc. | Modified Pasteurella multocida bacteria vaccines |
| US4506017A (en) * | 1981-04-17 | 1985-03-19 | Norden Laboratories, Inc. | Modified Pasteurella haemolytica bacteria |
| US4626430A (en) * | 1981-04-17 | 1986-12-02 | Norden Laboratories, Inc. | Processes for growth of modified Pasteurella haemolytica bacteria and preparation of a vaccine therefrom |
| US4559306A (en) * | 1981-04-17 | 1985-12-17 | Norden Laboratories, Inc. | Modified Pasteurella multocida bacteria |
| NL8200392A (en) * | 1982-02-03 | 1983-09-01 | Duphar Int Res | PROCESS FOR PREPARING AN IMMUNOGEN OF PASTEURELLA MULTOCIDA |
| JPH0662433B2 (en) * | 1984-04-23 | 1994-08-17 | 財団法人日本生物科学研究所 | Method for producing powdered vaccine of Haemophilus paragarinarum |
| EP0287206B2 (en) * | 1987-03-24 | 1999-11-24 | BTG INTERNATIONAL LIMITED (Company No. 2664412) | Vaccine against pasteurella |
| MX9301736A (en) * | 1992-03-30 | 1994-01-31 | Smithkline Beecham Corp | PASTEURELLA HAEMOLYTICA TYPE A-1 BACTERINE-TOXOID VACCINE. |
-
1973
- 1973-02-07 GB GB593573*[A patent/GB1441098A/en not_active Expired
- 1973-03-28 IL IL41902A patent/IL41902A/en unknown
- 1973-03-28 JP JP48035564A patent/JPS496118A/ja active Pending
- 1973-03-28 FR FR7311142A patent/FR2182909B1/fr not_active Expired
- 1973-03-28 NL NL7304320A patent/NL7304320A/xx unknown
- 1973-03-28 DE DE2315563A patent/DE2315563A1/en active Pending
- 1973-03-28 ES ES413100A patent/ES413100A1/en not_active Expired
- 1973-03-28 IT IT49108/73A patent/IT1035061B/en active
- 1973-03-29 HU HU73WE00000484A patent/HU171383B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES413100A1 (en) | 1976-06-01 |
| HU171383B (en) | 1977-12-28 |
| GB1441098A (en) | 1976-06-30 |
| DE2315563A1 (en) | 1973-10-11 |
| JPS496118A (en) | 1974-01-19 |
| IT1035061B (en) | 1979-10-20 |
| FR2182909B1 (en) | 1976-04-09 |
| NL7304320A (en) | 1973-10-02 |
| IL41902A0 (en) | 1973-05-31 |
| FR2182909A1 (en) | 1973-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mourad et al. | Passive immunization of mice against Candida albicans | |
| IL41902A (en) | Immunogenic substance,its production,vaccine preparations containing it and their preparation | |
| Angerman et al. | Comparative efficacy and toxicity of a ribosomal vaccine, acetone-killed cells, lipopolysaccharide, and a live cell vaccine prepared from Salmonella typhhimurium | |
| Egerton | Surface and somatic antigens of Fusiformis nodosus | |
| EP0020356A1 (en) | Pasteurellosis vaccines. | |
| BR112015013513B1 (en) | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION | |
| BR122016004924A2 (en) | ISOLATED POLYPEPTIDE AND IMMUNOGENIC COMPOSITIONS UNDERSTANDING THE SAME | |
| CA2402935A1 (en) | Adjuvant for vaccines | |
| Abrahams | Further studies on acquired resistance to murine cryptococcosis: enhancing effect of Bordetella pertussis | |
| US3928565A (en) | Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties | |
| US20100183675A1 (en) | Stable vaccine compositions and methods of use | |
| JP2015091795A (en) | Nasal mucosal vaccine composition | |
| CN101337070B (en) | Freeze-dried live attenuated hepatitis A vaccine and preparation method thereof | |
| WO2010084298A1 (en) | Stable vaccine compositions and methods of use | |
| US4057626A (en) | Process for detoxifying influenza B virus | |
| Collins et al. | Heat-Labile Antigens of Salmonella enteritidis II. Mouse-protection Studies | |
| Garçon et al. | Development and evaluation of AS04, a novel and improved adjuvant system containing 3-o-desacyl-4′-monophosphoryl lipid a and aluminum salt | |
| US3987164A (en) | Method for prevention of pseudomonas aeruginosa infections | |
| GB1256457A (en) | Diethylaminoethyldextran (deae-d) as adjuvant for vaccines for active immunisation | |
| CN106075420A (en) | Multivalent pneumococcal Type B hemophilus influenza combined vaccine | |
| WO2004108156A1 (en) | A INTRACUTANEOUS INJECTION COMBINED VACCINE INCLUDED HeVac AND BCG AND ITS PREPARATION METHOD | |
| EP0030166A1 (en) | Vaccine composition for dental caries | |
| CN106075430A (en) | Multivalent pneumococcal ACYW135 meningococcus combined vaccine | |
| EP3407899A1 (en) | Immunoprophylaxis for recurrent bacterial infections | |
| JPH11240844A (en) | Oral administration of pneumococcal antigen |